A phase 1, single center, placebo-controlled, interventional study to evaluate the safety, tolerability, and pharmacokinetic profiles in healthy subjects compared to placebo
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs OLX-10010 (Primary) ; OLX-10010 (Primary)
- Indications Hypertrophic scars
- Focus Adverse reactions
- Sponsors OliX Pharmaceuticals
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.
- 18 May 2019 Status changed from recruiting to active, no longer recruiting.
- 15 May 2019 Planned number of patients changed from 44 to 48.